All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019

X

Find Dermatology Drugs in Phase I Clinical Development in ISRAEL

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

BiomX

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

WRIB

Participation Not Confirmed

Update your events

BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting

Contact the Supplier

Lead Product(s): BX001

Therapeutic Area: Dermatology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2020

Details:

BiomX is developing BX001, its lead product candidate, to modify the appearance of acne prone skin.

Sol-Gel Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

WRIB

Participation Not Confirmed

Update your events

Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)

Contact the Supplier

Lead Product(s): SGT-210

Therapeutic Area: Dermatology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 02, 2020

Details:

The Phase 1 proof of concept study SGT-84-01 is a single-center, single-blinded, vehicle-controlled study designed to evaluate the bioavailability, safety, tolerability and efficacy of SGT-210.